We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Social Diagnostics Start-Up to Provide Simple, Affordable Tests Worldwide

By LabMedica International staff writers
Posted on 18 Aug 2014
The Royal Tropical Institute (KIT; Amsterdam, Netherlands) is establishing a nonprofit, social diagnostics company that develops and markets tests for the diagnosis of poverty-related diseases.

Infectious diseases have a global impact; they take no account of national borders and influence the stability of societies in matters of health and development. More...
Paul Klatser, unit manager at KIT Biomedical Research and Donald Kalff, investor and formerly a director at KLM and Shell, have joined forces in taking the initiative to establish "OneDiagnostics," with the ambition to improve the health of disadvantaged people worldwide. “I consider it a moral obligation to develop and share this type of knowledge. Both the private sector and governments are failing with regard to their support. In the Netherlands it is inconceivable to prescribe antibiotics for a fever without first having been examined by a doctor. This is however often the case in low- and middle-income countries. Not only does this leave people to remain ill or even die, it also increasingly leads to antibiotic resistance," said Mr. Klatser.

"In the ‘Western world’ we have the knowledge to treat most diseases effectively—with a timely diagnosis. The required medicines are affordable and available, also in low- and middle-income countries" said Mr. Klatser. "We are not restricting ourselves to only developing simple tests. We will also market them and invest in the correct provision of information about diagnostics and treatment, and our ultimate goal is local development and production.”

OneDiagnostics expects to need EUR 2.5 million for the start-up of the company. This would make it possible to market the first tests for brucellosis, leptospirosis, typhoid fever, and leishmaniasis. There are more plans, such as low-cost tests for tuberculosis, malaria, and a combined test for HIV and syphilis, especially intended for pregnant women in developing countries.

“We have a business plan and are now working hard to find funds to make a good start and we hope that investors will receive a small financial return in the future," said Mr. Klatser, "We will provide affordable, quality products with honest, scientifically substantiated information. The real benefit lies in the difference that OneDiagnostics will make with respect to the health of millions.”

Related Links:

Royal Tropical Institute (KIT)



Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
Collection and Transport System
PurSafe Plus®
New
Homocysteine Quality Control
Liquichek Homocysteine Control
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: A schematic illustrating the coagulation cascade in vitro (Photo courtesy of Harris, N., 2024)

ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners

Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read more

Microbiology

view channel
Image: EBP and EBP plus have received FDA 510(k) clearance and CE-IVDR Certification for use on the BD COR system (Photo courtesy of BD)

High-Throughput Enteric Panels Detect Multiple GI Bacterial Infections from Single Stool Swab Sample

Gastrointestinal (GI) infections are among the most common causes of illness worldwide, leading to over 1.7 million deaths annually and placing a heavy burden on healthcare systems. Conventional diagnostic... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.